Cereno Scientific’s patent portfolio continues to grow. This week, the biotech company announced being granted patents expanding the protection of CS1 to the European market, thus securing patent protection for its lead programme in nearly all global key markets. In addition, the company also announced that the first patent for preclinical programme CS585 has been granted by the US Patent Office.
This week was an important one for Swedish biopharma company Cereno Scientific in terms of IPR (Intellectual Property Rights), with two of its development programmes receiving patent protection: lead programme CS1 and preclinical programme CS585.
CS1 receives patent in Europe
CS1, being developed for the treatment of rare cardiovascular disease (CVD) Pulmonary Arterial Hypertension (PAH), is soon to be evaluated in a phase II clinical trial. In the runup to the study, the company has, until this week, secured patent protection for CS1 in most major global markets, including the US, Japan, Canada and Australia. Now, the company can add Europe to the list, as CS1’s first patent family has been granted patents in 15 European countries following a completed validation and opposition period.
The company’s CEO Sten R Sörensen expressed his satisfaction in a recent press release:
»It is great to obtain our first patent for CS1 in Europe. Adding this market to the already granted markets offers a good broad patent protection, which is generally an important factor when looking at an asset’s commercial potential.«
These new patents will add to an already wide market exclusivity.
First patent awarded to CS585
The company’s IPR news this week did not stop there. Just yesterday, Cereno Scientific announced the grant of the first patent in the company’s preclinical CS585 programme. The CS585 programme comprises stable, selective, and potent prostacyclin receptor agonists that have demonstrated potential to significantly improve on mechanisms relevant to selected cardiovascular diseases. The programme is currently undergoing a 2-year preclinical development plan in collaboration with the University of Michigan with the aim of a successful transition to a phase I clinical study.
According to the agreement made with the University of Michigan in March 2021, if the preclinical evaluation of CS585 is successful, Cereno can exercise its option to exclusively in-license the drug including its intellectual property rights for further clinical development and commercialisation.
Read more about CS585 here.
Cereno’s CEO commented on the importance of this first patent protecting the CS585 programme:
»It is very positive that the first patent has been obtained in the CS585 preclinical program. Receiving validation of the innovative nature of the research, which is a patent criterion, from one of the world’s largest markets is highly important in any stage of drug development. Our preclinical programs are key to the long-term success of Cereno, and a solid patent protection is a critical factor in a future commercialization of the drug candidates.«
The patent, granted by the US Patent Office (USPTO), is titled Hydroxyeicosatrienoic acid compounds and their use as therapeutic agents, US11111222, and covers a key strategic market for Cereno, the US. Being granted a patent in one of the world’s largest markets is important external validation of the inventiveness of the CS585 research programme.
Increased commercial potential
Overall, both granted patents support the company’s positioning ahead of future commercialisation.
The strong IPR protecting a diversified project portfolio with broad therapeutic potential will give Cereno expanded opportunities to increase commercial value of the company and its drug candidates moving forward.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.